NO20072687L - Farmasoytisk prevensjonspreparat - Google Patents

Farmasoytisk prevensjonspreparat

Info

Publication number
NO20072687L
NO20072687L NO20072687A NO20072687A NO20072687L NO 20072687 L NO20072687 L NO 20072687L NO 20072687 A NO20072687 A NO 20072687A NO 20072687 A NO20072687 A NO 20072687A NO 20072687 L NO20072687 L NO 20072687L
Authority
NO
Norway
Prior art keywords
daily dosage
ethinyl estradiol
administered
dienogest
pharmaceutically acceptable
Prior art date
Application number
NO20072687A
Other languages
English (en)
Inventor
Thomas Graser
Claus Claussen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20072687L publication Critical patent/NO20072687L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen vedrører et farmasøytisk preparat som inneholder dienogest ved en mengde som tilsvarer en daglig doseringsenhet på 1,5 mg eller 2,0 mg når preparatet blir administrert, og etinyløstradiol ved en mengde som tilsvarer en daglig doseringsenhet på 0,015 mg eller 0,020 mg når preparatet blir administrert, sammen med én eller flere farmasøytisk akseptable bærere i minst 21 daglige doseringsenheter. Oppfinnelsen vedrører ytterligere et oralt, farmasøytisk prevensjonspreparat inneholdende 1,5 mg 17a-cyanometyl-17ß-hydroksyøstra-4,9-dien-3-on (dienogest) og 0,015 eller 0,020 mg 17a-etinyløstradiol (etinyløstradiol) eller 2,0 mg dienogest og 0,015 mg etinyløstradiol sammen med én eller flere farmasøytisk akseptable bærer i minst 21 daglige doseringsenheter i en 28-dagers menstruasjonssyklus.
NO20072687A 2005-02-15 2007-05-25 Farmasoytisk prevensjonspreparat NO20072687L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003179A EP1690543A1 (de) 2005-02-15 2005-02-15 Pharmazeutisches Präparat zur Kontrazeption
PCT/EP2006/001354 WO2006087173A1 (de) 2005-02-15 2006-02-15 Pharmazeutisches präparat zur kontrazeption

Publications (1)

Publication Number Publication Date
NO20072687L true NO20072687L (no) 2007-11-13

Family

ID=34933759

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072687A NO20072687L (no) 2005-02-15 2007-05-25 Farmasoytisk prevensjonspreparat

Country Status (20)

Country Link
EP (2) EP1690543A1 (no)
JP (1) JP2008527018A (no)
KR (1) KR20070086380A (no)
CN (1) CN101119732A (no)
AR (1) AR053545A1 (no)
AU (1) AU2006215818A1 (no)
BR (1) BRPI0606724A2 (no)
CA (1) CA2590004A1 (no)
CR (1) CR9324A (no)
DO (1) DOP2006000035A (no)
EA (1) EA200701091A1 (no)
IL (1) IL183635A0 (no)
MX (1) MX2007009061A (no)
NO (1) NO20072687L (no)
PA (1) PA8663401A1 (no)
PE (1) PE20061291A1 (no)
TW (1) TW200640468A (no)
UA (1) UA85003C2 (no)
WO (1) WO2006087173A1 (no)
ZA (1) ZA200707910B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
WO2009049813A2 (de) * 2007-10-11 2009-04-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption
EP2055306A1 (de) * 2007-11-05 2009-05-06 Bayer Schering Pharma AG Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271386T1 (de) * 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält

Also Published As

Publication number Publication date
WO2006087173A1 (de) 2006-08-24
IL183635A0 (en) 2007-10-31
BRPI0606724A2 (pt) 2009-07-14
PE20061291A1 (es) 2006-12-07
PA8663401A1 (es) 2006-12-07
CN101119732A (zh) 2008-02-06
UA85003C2 (ru) 2008-12-10
EA200701091A1 (ru) 2008-02-28
DOP2006000035A (es) 2006-09-15
ZA200707910B (en) 2009-08-26
KR20070086380A (ko) 2007-08-27
TW200640468A (en) 2006-12-01
EP1690543A1 (de) 2006-08-16
AR053545A1 (es) 2007-05-09
CR9324A (es) 2007-10-11
EP1853273A1 (de) 2007-11-14
MX2007009061A (es) 2007-09-11
AU2006215818A1 (en) 2006-08-24
CA2590004A1 (en) 2006-08-24
JP2008527018A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
HRP20070188B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
NO327588B1 (no) Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
NO20072687L (no) Farmasoytisk prevensjonspreparat
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
TW200638951A (en) Solid oral pharmaceutical form for contraception
NO20091057L (no) Oral legemiddelform for prevensjon
SI1937274T1 (sl) Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
RS50849B (sr) Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive method
HRP20020666B1 (en) Drospirenone for hormone replacement therapy
RU2009140372A (ru) Новый режим с дроспиреноном/17b-эстрадиолом, фармацевтический комбинированный продукт и набор для выполнения этого режима
TH80558B (th) รูปแบบยาทางช่องปากชนิดแข็งสำหรับการคุมกำเนิด
TH54054B (th) สารผสมทางเภสัชกรรมสำหรับใช้เป็นยาคุมกำเนิด

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application